EXXUA
Mar 02, 2025
Long-Awaited Victory: Fabre-Kramer’s Major Depressive Disorder Treatment Drug Gains FDA Approval
Fabre-Kramer Pharmaceuticals’ major depressive disorder drug, gepirone, faced FDA rejection not once, not twice, but three times since the beginning of the 21st century. Finally, the company can rejoice as the FDA has granted long-awaited approval. On 29 September 2023, the FDA approved Fabre-Kramer Pharmaceuticals...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
